SPRO Spero Therapeutics, Inc.
Research report · from SEC EDGAR · close 2026-07-13
$2.18 +3.8%
$126.2M mkt cap
executive summary
Spero Therapeutics, Inc. (SPRO) is a $126.2M company. Revenue is $66.8M (+39.2% y/y) at a 13% net margin. It is profitable. Our health score is F (29/100). 3 red flags on file. It may need to raise cash (dilution risk).
Revenue (FY)
$66.8M
+39.2% y/y
⛔Going-concern warning
Auditor flagged substantial doubt about the company continuing for the next 12 months — a raise is usually required.
⛔Bankruptcy-risk zone
Altman Z-Score is in the distress zone (-0.01).
⚠One-sided insider selling
5 insider sales and no open-market buys in the recent window.
who's buying
Insider buys / sells
0 / 5
Cash & ST investments
$56.1M
Operating cash flow
-$12.6M
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-13 by stocktools.ai.